Versartis presents positive preclinical data on 2 product candidates at ENDO 09
Washington, DC June 10, 2009 Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, today presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (...New gene scanning technology marks a major advance in disease research
...bing, leading to more personalised medicine and screening.' Professor Day's group is using combinations of meltMADGE and a second technology called endo VII MADGE to explore variations in the whole population of disease genes relevant to growth, obesity and cardiovascular disease. ...Suppressing growth hormone in early adulthood may prevent cancer
...ay the onset or progression of several types of cancer, researchers from Wake Forest University School of Medicine and other centers reported today at endo 2005, the annual meeting of the Endocrine Society, in San Diego. Suppression of growth hormone and insulin-like growth factor (IGF-1) also may decre...